Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals REGN revealed 10 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $518,443, and 3 were calls, valued at $365,370.
Predicted Price Range
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $700.0 and $1000.0 for Regeneron Pharmaceuticals, spanning the last three months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 85.5 with a total volume of 234.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Regeneron Pharmaceuticals's big money trades within a strike price range of $700.0 to $1000.0 over the last 30 days.
Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | PUT | SWEEP | BEARISH | 08/15/25 | $73.0 | $70.0 | $73.0 | $720.00 | $270.1K | 6 | 37 |
| REGN | CALL | SWEEP | BULLISH | 06/20/25 | $37.1 | $37.0 | $37.1 | $820.00 | $241.1K | 9 | 65 |
| REGN | CALL | SWEEP | BEARISH | 12/18/26 | $77.0 | $73.0 | $73.0 | $1000.00 | $73.0K | 78 | 10 |
| REGN | PUT | SWEEP | NEUTRAL | 01/17/25 | $19.9 | $18.4 | $19.9 | $715.00 | $59.7K | 9 | 57 |
| REGN | PUT | SWEEP | BULLISH | 01/17/25 | $22.5 | $18.4 | $20.0 | $715.00 | $54.0K | 9 | 27 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Following our analysis of the options activities associated with Regeneron Pharmaceuticals, we pivot to a closer look at the company's own performance.
Regeneron Pharmaceuticals's Current Market Status
- Currently trading with a volume of 102,419, the REGN's price is up by 0.45%, now at $715.52.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 29 days.
What The Experts Say On Regeneron Pharmaceuticals
2 market experts have recently issued ratings for this stock, with a consensus target price of $365.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * In a cautious move, an analyst from Canaccord Genuity downgraded its rating to Hold, setting a price target of $165. * An analyst from B of A Securities downgraded its action to Underperform with a price target of $565.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
